Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.34 |
| ▸ | KDM1A | O60341 | 4/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23978833 | 0.86 | CRHR1 (0.43) | CRHR1KDM1ACHRNB2CHRNA4 | |
| SCHEMBL13948526 | 0.85 | CRHR1 (0.40) | CRHR1CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL26996830 | 0.82 | PRCP (0.36) | BIRC2CRHR1KDM1ANTRK1 | |
| SCHEMBL13948429 | 0.81 | CRHR1 (0.37) | CRHR1CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL18473007 | 0.79 | KDM1A (0.37) | BIRC2CRHR1KDM1ASIGMAR1 | |
| SCHEMBL21994980 | 0.79 | KDM1A (0.42) | BIRC2KDM1ASIGMAR1 | |
| SCHEMBL13948525 | 0.77 | CRHR1 (0.39) | CRHR1CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL18494387 | 0.77 | SIGMAR1 (0.37) | BIRC2KDM1ASIGMAR1 | |
| SCHEMBL22456834 | 0.72 | KDM1A (0.34) | BIRC2KDM1A | |
| SCHEMBL18976626 | 0.72 | CHRNB2 (0.40) | CHRNB2CHRNA4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870663-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870663-B2 | Compounds useful in HIV therapy | CCR5, SLC11A2, CD4 | BIRC2 2782/4885CRHR1 4038/4885KDM1A 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.